Xiamen Humanity Hospital
Breast cancer treatment cost in China typically includes essential diagnostics like CT of the chest, which runs from $300 to $600. Primary surgical interventions such as a mastectomy range from $8,500 to $16,500, while chemotherapy for breast cancer costs $14,800 to $31,000. Total expenses depend on the clinical stage and clinic tier, often offering 50-70% savings compared to the US. Top cities for treatment include Guangzhou and Xiamen.
Typical Breast Cancer Treatment Costs in China
Bookimed Expert Insight: Advanced-stage patients find high value in specialized centers like Fuda Cancer Hospital. They provide minimally invasive alternatives like NanoKnife and cryosurgery for complex cases. For those seeking radiation expertise, Professor Liu Shi Xin at Xiamen Humanity Hospital offers advanced IMRT and VMAT protocols. International patients benefit from JCI-accredited standards while maintaining significant cost advantages. Early-stage detection remains the most cost-effective path for long-term recovery.
| China | Turkey | Austria | |
| Tomotherapy | from $17,500 | from $8,440 | from $30,000 |
| Resveratrol IV Therapy | from $350 | from $200 | from $600 |
| Radiotherapy for breast cancer | from $14,500 | from $8,730 | from $10,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $3,250 | from $12,000 |
| Proton therapy for breast cancer | from $38,500 | from $30,000 | from $55,000 |
Dr. Luan Tianyan, MD, is Head of Oncology. He was recruited to Hainan Province as a high-level talent. He is a visiting scholar at the Dana-Farber Cancer Institute (USA). He is also Director of the Clinical Research Office at Bozheng Hengda International Hospital. He serves on the standing committees of the Clinical Research Management Committee (Southern Oncology Clinical Research Association), the Immunotherapy Committee (Hainan Provincial Anti-Cancer Association), and the Hainan Province Drug Research Committee.
He has more than 20 years of oncology practice. He provides individualized, comprehensive care for gastrointestinal tumors, lung cancer, and breast cancer. He focuses on pain management, palliative care, and psychological support in advanced cancer. He also works on the clinical use and study of tumor immunotherapy, including personalized mRNA vaccines and CAR-T therapy. He develops and applies proprietary drugs and related technologies.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Written by Anna Leonova
China offers high-quality breast cancer treatment in JCI-accredited urban centers. Early-stage survival rates exceed 90% in top-tier facilities. Specialized hospitals in Beijing and Shanghai align with international MDT protocols. Advanced technologies like NanoKnife and CyberKnife M6 provide precise, minimally invasive alternatives for complex cases.
Bookimed Expert Insight: While many seek traditional surgery, China excels in combining immunotherapy with unique ablation techniques. Fuda Cancer Hospital has treated over 30,000 patients from 100 countries using cryosurgery and microwave hyperthermia. This high volume of international cases suggests these specialized protocols are particularly effective for advanced or metastatic breast cancers that require more than standard chemotherapy.
Patient Consensus: Patients note that top-tier urban hospitals provide care rivaling global standards, though they emphasize the need for a translator. Many choose these centers specifically for access to minimally invasive therapies not always available in their home countries.
Advanced breast cancer therapies in China include next-generation antibody-drug conjugates (ADCs) like Trastuzumab Deruxtecan and Sacituzumab Tirumotecan. Patients access innovative targeted therapies, bispecific antibodies, and specialized radiosurgery. Facilities like Fuda Cancer Hospital utilize minimally invasive techniques and cryosurgery for advanced-stage cases.
Bookimed Expert Insight: China has emerged as a primary launch market for global oncology innovations. Some ADCs receive regulatory approval here before other major international bodies. For instance, the Jinshazhou Hospital offers CyberKnife M6 treatments for approximately $7,700 (56,000 CNY). This reflects a trend where high-end technology is bundled with comprehensive logistics like clinic transfers.
Patient Consensus: Patients note that top-tier hospitals provide rapid access to clinical trials for metastatic triple-negative cases. They emphasize the importance of using professional coordinators to navigate language barriers and verify legitimate treatments at state-affiliated centers.
China offers advanced minimally invasive breast cancer treatments including NanoKnife, cryosurgery, and vascular interventional therapy. Specialized centers in Guangzhou utilize these technologies to treat tumors without traditional systemic chemotherapy side effects. These methods target cancer cells while preserving surrounding healthy breast tissue and critical structures.
Bookimed Expert Insight: Data from Fuda Cancer Hospital shows they apply over 10 types of minimally invasive therapies. A key differentiator in China is the high volume of international patients. Fuda alone has treated over 30,000 patients from 100 countries. This suggests a highly standardized protocol for international cases often missing in smaller regional clinics.
Patient Consensus: Patients note that urban centers like Guangzhou provide better access to breast-conserving options. Many emphasize that having a medical advocate is essential for navigating these specialized Chinese oncology treatments.
Major Chinese hospitals provide dedicated support for international patients through specialized International Medical Departments or VIP wings. These units offer bilingual staff, English medical documentation, and streamlined services. Facilities in cities like Guangzhou and Shanghai often hold JCI accreditation to ensure global healthcare standards.
Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital demonstrate their international focus by treating 30,000 patients from over 100 countries. Data shows that top-tier facilities often employ doctors with extensive global experience. For example, Dr. Leng Yin practiced at major hospitals in Thailand before joining Fuda, ensuring a better understanding of international patient expectations.
Patient Consensus: Patients note that while major cancer centers provide liaison officers and English paperwork, bringing a private interpreter is helpful for complex medical discussions. Many emphasize that using hospital WeChat accounts is the most effective way to coordinate arrival and confirm services beforehand.
Family members are generally allowed to stay with breast cancer patients in China. Most major hospitals permit one designated caregiver to stay overnight in the patient room. Facilities typically provide a folding chair or cot. Access often requires a specific companion card and valid identification like a passport.
Bookimed Expert Insight: While public hospitals offer basic folding chairs for companions, JCI-accredited centers like Fuda Cancer Hospital in Guangzhou manage high international patient volumes with more supportive structures. Our data shows these facilities often accommodate families better because they are used to patients traveling from over 100 countries. If you are choosing between a tier-3 public ward and a specialized center, the latter is more likely to have established protocols for international family support.
Patient Consensus: Patients note it is essential to bring your own bedding and snacks since hospital provisions for caregivers are often very basic. Many emphasize that having a male relative stay in female wards can sometimes face local restrictions, so confirming specific ward rules early is vital.
To obtain a medical visa for breast cancer treatment in China, you must secure an official invitation letter from a Grade 3A hospital. Applicants typically require a short-term S2 visa for stays under 180 days. Complex oncology cases exceeding six months require an S1 visa converted into a medical stay permit.
Bookimed Expert Insight: While many search for general medical visas, targeting JCI-accredited facilities like Fuda Cancer Hospital in Guangzhou can simplify the process. These centers manage high international volumes of over 30,000 patients and have established protocols for issuing the specific invitations required by consulates. This institutional experience often reduces the 4–6 week administrative delays common at smaller, non-accredited hospitals.
Patient Consensus: Patients emphasize that paperwork mismatches are common and suggest translating all medical records early. Many note that getting a guarantee from a top-tier hospital is the only way to avoid visa rejection.
Recommended hospitals for breast cancer in China include Peking Union Medical College Hospital and Fudan University Shanghai Cancer Center. These institutions lead national rankings for multidisciplinary care. Specialized centers like JCI-accredited Fuda Cancer Hospital in Guangzhou offer advanced treatments, including cryosurgery and targeted therapies.
Bookimed Expert Insight: While public giants like Fudan University Shanghai Cancer Center are prestigious, they often have two-month wait times. International patients find better efficiency at JCI-accredited private centers in Guangzhou. These facilities, such as Fuda Cancer Hospital, manage over 30,000 international cases and prioritize rapid treatment starts.
Patient Consensus: Patients note that top public hospitals are very crowded and may have long waits. Many suggest choosing facilities with dedicated international departments to ensure better communication and faster access to specialists.